The Bottom Line for Leadership
- Implementing Regulation (EU) 2025/1466 is in full effect as of February 12, 2026, marking the most significant overhaul of EU pharmacovigilance rules since 2012.
- Non-compliant organizations face regulatory inspection exposure, potential market access consequences, and reputational risk.
- This document outlines what the regulation requires and what your team needs to do.
- UBC has already helped clients achieve compliance across all five key regulatory areas, completing 30+ inspections and zero critical findings.
The Regulatory Moment Is Here
Implementing Regulation (EU) 2025/1466, published July 22, 2025 and fully applicable as of February 12, 2026, is the first substantive amendment to the EU pharmacovigilance framework since 2012. This is not incremental fine-tuning. It redefines how marketing authorization holders (MAHs) must monitor safety data, manage third parties, conduct audits, and document their pharmacovigilance systems.
Organizations that treat this as a routine compliance update are taking on unnecessary risk. The regulation introduces binding obligations with direct inspection implications. Gaps in third-party/vendor contract governance and auditing, signal management procedures, and PSMF documentation are exactly the areas regulators are scrutinizing.
UBC is ready. We have prepared clients for these requirements across all compliance dimensions and we are positioned to deploy that expertise to your organization immediately.
Six Requirements That Demand Immediate Attention
The regulation’s phased implementation means some obligations took effect in August 2025 (EudraVigilance monitoring and signal management). All remaining provisions, covering pharmacovigilance system master files, subcontracting, periodic safety update reports, post-authorization safety studies, and technical reporting standards, became fully applicable on February 12, 2026. Here is what your compliance team must own right now.
1. EudraVigilance Monitoring and Signal Management
MAHs must actively monitor EudraVigilance data in parallel with other safety sources, not as an optional supplement but as a required integrated input. Critically, the regulation also shifts primary signal validation responsibility: MAHs no longer validate signals identified through EudraVigilance database monitoring. That responsibility now rests with the EMA and National Competent Authorities. Signal management for MAHs must focus specifically on suspected adverse reactions identified through their own monitoring activities, handled through internal procedures aligned with GVP Module IX.
Critical operational implication: Standalone signal notification forms to the EMA are no longer the mechanism. Internal SOPs and role definitions must be updated to reflect this shift. If your signal management workflow still references the prior process, you are out of compliance.
Signal management SOPs should be reviewed now, and your data infrastructure must connect EudraVigilance with all other safety sources in real time.
2. Third-Party Contract Governance
This is where many organizations are most exposed. Contracts with pharmacovigilance subcontractors must now explicitly define: roles and responsibilities, safety data exchange obligations, audit and inspection arrangements, and limitations on further subcontracting without the MAH’s written consent.
Regulators can inspect subcontractors directly, regardless of whether the subcontract explicitly states this obligation. Service providers who resist audit rights create compliance liability for the MAH. Organizations with legacy vendor agreements that predate these requirements must treat contract remediation as a priority, not a back-burner project.
A full inventory of PV subcontracting agreements is the starting point. Gaps against the new contract requirements should be identified and renegotiation initiated where needed.
3. Risk-Based Audit Programs
The new regulation strengthens audit requirements significantly. Audits must cover all PV activities performed by the MAH and its subcontractors over a defined period, conducted by personnel independent of the audited processes, using a risk-based interval system. Subcontractors must be audited commensurate with the criticality of their functions.
A well-designed audit program is not a cost center; it is your strongest evidence of a functioning pharmacovigilance system in the event of regulatory inspection. Organizations that invest in strategic, risk-calibrated audit programs demonstrate quality culture to inspectors. Those with ad hoc or under-resourced audit programs are exposed.
A documented, risk-stratified audit schedule covering both internal PV activities and all relevant vendors is essential, with auditor independence built into the operating model.
4. Pharmacovigilance System Master File (PSMF) Updates
The PSMF requirement has been refined: MAHs need only document major or critical deviations from pharmacovigilance procedures, not every minor deviation. This reduces administrative burden, but it also raises the stakes for what is documented. The PSMF must reflect the actual state of your PV system, including all subcontracting arrangements and QPPV oversight.
Inspectors use the PSMF as a roadmap into your compliance posture. An outdated or incomplete PSMF signals systemic weakness. An accurate, current PSMF, aligned with your live operations and updated subcontract arrangements, demonstrates operational control.
The PSMF should be reviewed and updated to reflect the new subcontracting structure, and deviation documentation protocols must align with the major/critical threshold.
5. Expanded PSUR and PASS Requirements
From February 12, 2026, periodic safety update reports must include updates on the implementation of risk minimization measures (RMMs), not just effectiveness assessment results. This requires active cross-functional coordination between safety surveillance, medical affairs, risk management, and commercial teams.
Additionally, non-interventional post-authorization safety studies must now be registered electronically with the EMA, with protocols and final reports submitted to the electronic PASS study register. This enhances regulatory transparency and creates a clear documentation trail that inspectors will reference.
Cross-functional RMM tracking processes need to be in place, PSUR templates should reflect the new content requirements, and electronic PASS registration must be implemented for all qualifying studies.
6. Literature Reporting Standards and ICSR Requirements
Two additional technical areas of the regulation are often overlooked in compliance planning but carry real operational implications for literature monitoring teams and case processing functions.
Literature case reporting now requires Digital Object Identifier (DOI) inclusion, and outputs must conform to updated IDMP, MedDRA, and ISO standards. These changes are designed to improve traceability and interoperability across regulatory systems, but they require updates to literature screening workflows, reporting templates, and the tools used to generate case outputs. Organizations running literature review programs through legacy systems or manual processes should confirm their outputs meet the new format requirements.
On the case processing side, the regulation strengthens baseline requirements for Individual Case Safety Reports (ICSRs) across all reporting types, not only expedited reports. Every ICSR must include at minimum one identifiable reporter, one identifiable patient, at least one suspected adverse reaction, and the medicinal product concerned. While this reflects existing practice for most well-run PV programs, it codifies the standard and gives inspectors a clear basis for evaluating case completeness. Quality control processes for routine cases should be reviewed against this baseline.
How the Industry Is Responding
Across the pharmaceutical and biopharmaceutical sector, organizations are taking decisive action on the same compliance dimensions covered in this piece. The regulatory and consulting community, including major law firms and specialized PV service providers, consistently points to third-party contract remediation, signal management SOP updates, and literature reporting system alignment as the most time-sensitive gaps. Gap analysis against the new subcontracting requirements, coupled with cross-functional implementation teams that include regulatory, quality, and legal representation, is the standard approach organizations are taking.
The cost and complexity of compliance scales significantly by organization size and current maturity. Large pharmaceutical companies with established PV systems may require primarily procedural updates. Smaller biotech and specialty pharma organizations may require comprehensive system overhauls. In both cases, the organizations achieving compliance fastest are those working with experienced partners who already have the regulatory infrastructure, contract frameworks, and audit programs in place.
What is clear across the industry: this regulation makes MAH accountability more visible, not more optional. The obligations were there before, and now they are harder to ignore, and regulators have clearer inspection criteria to enforce against.
UBC Delivers Compliance, Not Just Guidance
UBC’s pharmacovigilance practice is already aligned with the 2025/1466 requirements. Our clients deploy proven systems, established governance frameworks, and a team that has navigated 30+ regulatory inspections without a single critical finding, rather than building from the ground up.
Integrated Technology That Meets the Monitoring Standard
The requirement to monitor and use EudraVigilance data alongside multiple safety sources demands integrated infrastructure. UBC’s purpose-built pharmacovigilance software automates real-time signal detection and management, literature review, and safety case processing, connecting EudraVigilance with your complete safety data environment. Literature review outputs are generated in conformance with the updated IDMP, MedDRA, and ISO standards, including DOI inclusion, and ICSR quality control processes reflect the strengthened baseline requirements across all case types. Your team spends time on analysis and decisions, not on manual data consolidation.
Full-Service Outsourcing With Built-In Governance
For organizations seeking to optimize their compliance footprint or expand European operations, UBC’s full-service outsourcing model delivers against all facets of the PV program, from safety database configuration and case processing through regulatory submissions, signal detection, literature screening, and safety writing. Our governance framework is designed as a transparent extension of your PV team, with clear audit rights and accountability structures that satisfy the new subcontracting requirements.
European Infrastructure Ready to Deploy
UBC provides Qualified Person for Pharmacovigilance (QPPV) services, establishes and maintains Pharmacovigilance System Master Files, handles EudraVigilance registration, and provides local QPPVs and National Contact Persons across EEA countries, the UK, and Switzerland. If your European PV infrastructure has gaps, we fill them immediately.
UBC Pharmacovigilance Services: What We Deliver
- Full-Service Outsourcing: End-to-end PV program management with complete delivery across all program facets
- European Post-Marketing Support: QPPV services, PSMF establishment and maintenance, EudraVigilance registration, local QPPVs and National Contact Persons (EEA, UK, Switzerland)
- Safety Case Processing & Reporting: 58,000+ cases processed annually with 99% on-time regulatory submission compliance
- Signal Detection & Management: Real-time identification and validation aligned with FDA guidance, EMA GVP Module IX, and CIOMS VIII
- Literature Review: Global and local screening using validated tools, with outputs conforming to updated IDMP, MedDRA, and ISO standards including DOI inclusion requirements
- Safety Writing: PSURs, PBRERs, DSURs, and aggregate safety reports
- Technology Solutions: Purpose-built PV software automating critical business processes
- Regulatory Intelligence: Continuous global and regional PV requirement monitoring through our PV Process Excellence Team
Beyond Compliance: Building for What’s Next
The February 2026 requirements set a new compliance baseline, and regulatory expectations in Europe will continue to evolve. Regulatory authorities are moving toward greater reliance on real-world data, patient-reported outcomes, and surveillance frameworks designed for novel therapies. Organizations that invest now in flexible PV infrastructure will be better positioned to adapt as those expectations develop.
This means building data platforms that can incorporate diverse data types, developing analytics capabilities that include advanced statistical methods, establishing patient engagement strategies that support direct safety reporting, and maintaining regulatory intelligence functions that identify changes before they become compliance deadlines. GVP Module IX is scheduled for a Q2 2026 update. Organizations with the right infrastructure in place today will adapt with minimal disruption.
UBC’s clients are not just compliant; they are positioned ahead of the regulatory curve. Our Regulatory Intelligence function continuously monitors global and regional PV requirements, translating emerging obligations into operational readiness before deadlines arrive.
Your Next Step
The regulation is in effect. The question is whether your pharmacovigilance program reflects that reality. UBC’s team of safety experts is ready to conduct a rapid gap assessment and deploy the solutions your program needs, whether that means targeted contract remediation, PSMF updates, signal management realignment, or comprehensive outsourcing.
Contact UBC today to assess your compliance posture and determine where immediate action is required.
About UBC
United BioSource LLC (UBC) is the leading provider of evidence development solutions with expertise in uniting evidence and access. UBC helps biopharma mitigate risk, address product hurdles, and demonstrate safety, efficacy, and value under real-world conditions. UBC leads the market in providing integrated, comprehensive clinical, safety, and commercialization services and is uniquely positioned to seamlessly integrate best-in-class services throughout the lifecycle of a product.
About the Author
Peter P. Psarologos, M.D., MPhil, Senior QPPV
Peter P. Psarologos, M.D., MPhil is a subject matter expert with over two decades of experience in the pharmaceutical industry. He currently serves as Senior Qualified Person for Pharmacovigilance (QPPV) at United BioSource Limited (UBC), where he leads pharmacovigilance operations and regulatory compliance across global and European markets. Over the course of his career, he has held senior leadership positions in drug safety and pharmacovigilance at international pharmaceutical organisations, contributing to the successful market authorisation of multiple breakthrough therapies, including oncological immune therapies and treatments for genetic disorders, in both the EU and the United States. Dr. Psarologos holds a Doctor of Medicine from the University of Novi Sad and a Master of Philosophy in Health Management, Economics and Policy from the University of Oslo. He is a recognised speaker at international pharmacovigilance conferences, most recently presenting at the World Drug Safety Congress Europe in Amsterdam
